NeuroSense Therapeutics Ltd

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

CAMBRIDGE, Mass. , April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSense Lonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of work BASEL, Switzerland and CAMBRIDGE, Mass. , April 9, 2024 /PRNewswire/ -- Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd.

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

CAMBRIDGE, Mass. , April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression Further analysis of PARADIGM is on track with neurofilament results expected in Q1 and TDP-43 and ProstaglandinJ2 biomarkers expected in the first half of 2024 CAMBRIDGE, Mass. , Feb. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Biogen

HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis.

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass. , Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

NEW YORK, NY, December 15, 2023 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company's lead drug candidate for amyotrophic lateral sclerosis (ALS).

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

A  statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) population analysis Neurofilament biomarker results from Biogen collaboration expected in January 2024 Primary biomarker endpoints, TDP-43 and Prostagladin2, are expected in H1 2024 PrimeC's meaningful effect magnitude, strong safety profile, and unique mechanism of action will be discussed with the FDA and other regulatory agencies in an End of Phase 2 meeting in H1 2024 CAMBRIDGE, Mass. , Dec. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and tolerability profile comparable to placebo Meaningful slowing of disease progression: 29% difference (P=0.12) in favor of ALSFRS-R outcome for patients treated with PrimeC vs placebo Slow Vital Capacity: observed a positive trend in favor of patients treated with PrimeC compared to placebo Neurofilament biomarker results from Biogen collaboration expected in January 2024 Primary biomarker endpoints and exploratory biomarkers from this trial, expected in H1 2024 Company to host webcast conference call to present data today at 8:30 AM EST CAMBRIDGE, Mass. , Dec. 5, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue treatment with PrimeC  First patient in Phase 2 Alzheimer's disease study expected to be enrolled December 2023 Cash runway beyond topline clinical study readouts, into Q2 2024 CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass. , Nov. 9, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

Clinical efficacy results ( s econdary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to be reported H1 2024  CAMBRIDGE, Mass. , Nov. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Participate in BIO-Europe Fall

HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2023 / Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive disorder that affects motor neurons, leading to muscle weakness, paralysis and ultimately death.

Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC

Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass. , Oct. 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense CEO Provides Q3 2023 Update

NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the company's most pivotal event since its IPO at the end of 2021. The company is also targeting Alzheimer's and Parkinson's with the same drug candidate under different names.

NeuroSense: A Hold Ahead Of Phase 2b ALS Data

In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing induced pluripotent stem cells (iPSCs) generated from people living with ALS Results reinforce previous findings in multiple models  In a previous independent study carried out by Dr. Ichida, PrimeC performed among the best in improving motor neuron survival when compared to several other ALS drugs in development and two ALS FDA approved drugs CAMBRIDGE, Mass. , Oct. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

SME status offers regulatory guidance and engagement in dialogue with EMA NeuroSense to open an EU office in Ulm, Germany Company plans to enroll patients at multiple sites across Europe in its planned Phase 3 pivotal ALS study of PrimeC CAMBRIDGE, Mass. , Sept. 20, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

European Medicines Agency Grants NeuroSense SME Status

Patents valid through 2038 Clinical t opline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass. , Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

News for NeuroSense Therapeutics Ltd Stock (NRSN)